Although near‐infrared (NIR)‐light‐mediated photothermal thrombolysis has been investigated to overcome the bleeding risk of clinical clot‐busting agents, the secondary embolism of post‐phototherapy fragments (>10 µm) for small vessels should not be ignored in this process. In this study, dual‐modality photothermal/photodynamic thrombolysis is explored using targeting nanoagents with an emphasis on improving biosafety as well as ameliorating the thrombolytic effect. The nanoagents can actively target glycoprotein IIb/IIIa receptors on thrombus to initiate site‐specific thrombolysis by hyperthermia and reactive oxygen species under NIR laser irradiation. In comparison to single photothermal thrombolysis, an 87.9% higher re‐establishment rate of dual‐modality photothermal/photodynamic thrombolysis by one‐time treatment is achieved in a lower limb thrombosis model. The dual‐modality thrombolysis can also avoid re‐embolization after breaking fibrin into tiny fragments. All the results show that this strategy is a safe and validated protocol for thrombolysis, which fits the clinical translational trend of nanomedicine.
In article number
1901378
, Qi Yang, Huiyu Liu, and co‐workers develop a dual modality photothermal/photodynamic thrombolytic strategy via targeting nanoagents with GPIIb/IIIa receptors targeting agents, effectively breaking the fibrin skeleton and preventing high bleeding risk of systematic fibrinolytic therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.